Illumina, SynapDx Join Forces on ASD | GenomeWeb

NEW YORK (GenomeWeb News) – SynapDx today announced a deal with Illumina aimed at the detection of autism spectrum disorders.

The deal will link SynapDx's autism technologies with Illumina's sequencing platforms to develop tools for the early detection of ASDs, SynapDx said, adding that the companies will also broadly evaluate other opportunities in neurodevelopment.

Further terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.